Skip to main content

Advertisement

SpringerLink
Log in

Pupillometry as an indicator of l-DOPA dosages in Parkinson’s disease patients

  • Neurology and Preclinical Neurological Studies - Original Article
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

A Correction to this article was published on 11 April 2018

This article has been updated

Abstract

Dopamine was shown to induce mydriasis by excitation of alpha-adrenergic receptors at the dilator pupillae muscle. Pupilla diameter may thus serve as an indirect measure of peripheral pharmacokinetics of l-DOPA and dopamine. The aim of this study is to evaluate the effect of l-DOPA dosage on pupillometric parameters in Parkinson’s disease (PD) patients. Sixteen PD patients and 14 healthy control subjects (CS) were studied. The statistical analysis revealed significant differences between CS and PD patients for the mean maximum and minimum pupil diameters (p = 0.017, p = 0.028, respectively), with higher values found in PD. Moreover, a significant dose–response relationship was found between the maximum pupil diameter and both the morning l-DOPA dose (R 2 = 0.78) and the total daily l-DOPA dose (R 2 = 0.93). A sigmoid-shaped curve best describes the dose–response relationship, with a ceiling effect at about 400 mg l-DOPA daily dose. In conclusion, measuring pupillometric parameters represents a sensitive tool for non-invasive evaluation of the peripheral effect of l-DOPA, especially with daily doses below 400 mg l-DOPA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Change history

  • 11 April 2018

    Unfortunately, original article has been published without acknowledgement section.

Abbreviations

BDI:

Beck depression inventory

CS:

Control subjects

D1, D2:

Dopamine receptors

DIF:

Difference between MAX and MIN

FAB:

Frontal assessment battery

MAX:

Maximum pupil parameter

MIN:

Minimum pupil parameter

MMSE:

Mini-mental state examination

PD:

Parkinson’s disease

R 2 :

R-squared for nonlinear regression

T :

Latency for the onset of constriction

UPDRS:

Unified Parkinson’s disease rating scale

VAR:

Variation ((MAX − MIN)/MAX) × 100

VCmax :

Maximum constriction velocity

References

  • Fotiou F, Goulas A, Fountoulakis K, Koutlas E, Hamlatzis P, Papakostopoulos D (1998) Changes in psychophysiological processing of vision in myasthenia gravis. Int J Psychophysiol 29(3):303–310

    Article  CAS  PubMed  Google Scholar 

  • Fotiou DF, Stergiou V, Tsiptsios D, Lithari C, Nakou M, Karlovasitou A (2009) Cholinergic deficiency in Alzheimer’s and Parkinson’s disease: evaluation with pupillometry. Int J Psychophysiol 73(2):143–149

    Article  CAS  PubMed  Google Scholar 

  • Giza E, Fotiou D, Bostantjopoulou S, Katsarou Z, Karlovasitou A (2011) Pupil light reflex in Parkinson’s disease: evaluation with pupillometry. Int J Neurosci 121(1):37–43

    Article  PubMed  Google Scholar 

  • Giza E, Fotiou D, Bostantjopoulou S, Katsarou Z, Gerasimou G, Gotzamani-Psarrakou A, Karlovasitou A (2012) Pupillometry and 123I-DaTSCAN imaging in Parkinson’s disease: a comparison study. Int J Neurosci 122(1):26–34

    Article  CAS  PubMed  Google Scholar 

  • Gordan R, Gwathmey JK, Xie LH (2015) Autonomic and endocrine control of cardiovascular function. World J Cardiol 7(4):204–214

    Article  PubMed  PubMed Central  Google Scholar 

  • Jain S (2011) Multi-organ autonomic dysfunction in Parkinson disease. Parkinsonism Relat Disord 17(2):77–83

    Article  PubMed  Google Scholar 

  • Langer SZ (1980) Presynaptic regulation of the release of catecholamines. Pharmacol Rev 32(4):337–362

    CAS  PubMed  Google Scholar 

  • Matouskova O, Slanar O, Chytil L, Perlik F (2010) Pupillometry in healthy volunteers as a biomarker of tramadol efficacy. J Clin Pharm Ther 36(4):513–517

    Article  PubMed  Google Scholar 

  • Micieli G, Tassorelli C, Martignoni E, Pacchetti C, Bruggi P, Magri M, Nappi G (1991) Disordered pupil reactivity in Parkinson’s disease. Clin Auton Res 1(1):55–58

    Article  CAS  PubMed  Google Scholar 

  • Navailles S, Carta M, Guthrie M, De Deurwaerdere P (2011) l-DOPA and serotonergic neurons: functional implication and therapeutic perspectives in Parkinson’s disease. Central Nerv Syst Agents Med Chem 11(4):305–320

    Article  CAS  Google Scholar 

  • Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE (2017) Parkinson disease. Nat Rev Dis Primers 3:17013

    Article  PubMed  Google Scholar 

  • Shannon RP, Mead A, Sears ML (1976) The effect of dopamine on the intraocular pressure and pupil of the rabbit eye. Invest Ophthalmol 15(5):371–380

    CAS  PubMed  Google Scholar 

  • Slanar O, Nobilis M, Kvetina J, Idle JR, Perlik F (2006) CYP2D6 polymorphism, tramadol pharmacokinetics and pupillary response. Eur J Clin Pharmacol 62(1):75–76 (author reply 77–78)

    Article  PubMed  Google Scholar 

  • Slanar O, Nobilis M, Kvetina J, Mikoviny R, Zima T, Idle JR, Perlik F (2007) Miotic action of tramadol is determined by CYP2D6 genotype. Physiol Res 56(1):129–136

    CAS  PubMed  Google Scholar 

  • Spiers AS, Calne DB, Vakil SD, French TM (1971) Action of thymoxamine on mydriasis induced by levodopa and dopamine. Br Med J 2(5759):438–439

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Stergiou V, Fotiou D, Tsiptsios D, Haidich B, Nakou M, Giantselidis C, Karlovasitou A (2009) Pupillometric findings in patients with Parkinson’s disease and cognitive disorder. Int J Psychophysiol 72(2):97–101

    Article  PubMed  Google Scholar 

  • Tambasco N, Romoli M, Calabresi P (2017) Levodopa in Parkinson’s disease: current status and future developments. Curr Neuropharmacol. https://doi.org/10.2174/1570159X15666170510143821

    PubMed  Google Scholar 

  • Velasco M, Luchsinger A (1998) Dopamine: pharmacologic and therapeutic aspects. Am J Ther 5(1):37–43

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic

    O. Bartošová, M. Šíma, F. Perlík & O. Slanař

  2. Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic

    C. Bonnet, O. Ulmanová & E. Růžička

Authors
  1. O. Bartošová
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Bonnet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O. Ulmanová
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Šíma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Perlík
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Růžička
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. O. Slanař
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O. Bartošová.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bartošová, O., Bonnet, C., Ulmanová, O. et al. Pupillometry as an indicator of l-DOPA dosages in Parkinson’s disease patients. J Neural Transm 125, 699–703 (2018). https://doi.org/10.1007/s00702-017-1829-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-017-1829-1

Keywords

Search

Navigation